Lumos Diagnostics Expands FebriDx Test to 265 U.S. Sites
Urgent care operators are seeing increased availability of rapid respiratory testing as Lumos scales its distribution network.
Updated on Oct. 27, 2026 in Economic Indicators
Live Poll
Does increased availability of rapid diagnostic tests in local clinics improve health outcomes in your community?
Lumos Diagnostics has expanded its U.S. commercial footprint for the FebriDx test to 265 sites as of October 11, 2026. This rollout, supported by a 351% surge in product sales, marks a significant scaling effort for the point-of-care diagnostic provider.
Why it matters
The company’s growth reflects a strategic push to capture market share within the U.S. urgent care sector ahead of the peak respiratory season. By investing $1 million in inventory, Lumos is positioning its logistics to meet anticipated volume spikes in its 29-state network.
Total quarterly revenue reached US$2 million, driven by a 351% increase in FebriDx product sales year-on-year. The company maintains US$11.8 million in cash reserves to support operations across 265 healthcare sites, up from 215 sites in mid-September.
The players
Lumos Diagnostics
A developer of rapid point-of-care diagnostic technology focused on the U.S. respiratory testing market.
The details
Lumos Diagnostics is executing a targeted rollout strategy by focusing on the nation’s top 100 urgent care operators. To sustain this trajectory, the company upgraded its Carlsbad manufacturing facility, projecting an annual production capacity of 10 million units. Simultaneously, the firm is adding three hospital emergency departments in the second quarter of FY27 to bolster clinical enrolment for its ongoing paediatric study.
Timeline
Mid-September 2026: Lumos operated 215 FebriDx sites across 26 states.
October 11, 2026: The company reached 265 active FebriDx healthcare sites.
Q2 FY27: Three hospital emergency departments are added to clinical studies.
Market Landscape
The company is following an established growth trajectory for point-of-care providers, moving from initial validation to high-volume commercial scaling. This mirrors the industry-wide push to secure prime positioning in urgent care networks following FDA 510(k) clearance.
Operators in the urgent care sector should evaluate how rapid testing integration impacts clinical throughput and patient wait times during peak respiratory seasons. As manufacturers like Lumos scale production, supply chain reliability for point-of-care consumables remains a critical procurement metric to monitor.
The takeaway
Lumos Diagnostics is successfully scaling its footprint through targeted partnerships with urgent care operators. Management teams should track the upcoming paediatric study results, as a new indication could potentially increase the addressable market by 15% to 20% in the near term.
What happens next
Lumos plans to incorporate three additional hospital emergency departments into its clinical studies during the second quarter of FY27.
Further reading
For broader trends in medical technology distribution, explore our coverage of Economic Indicators.
Source note: This article includes information reported by Proactiveinvestors NA.
Live Poll
Does increased availability of rapid diagnostic tests in local clinics improve health outcomes in your community?
